Showing 1,041 - 1,060 results of 104,570 for search '(( 2 de decrease ) OR ( 5 ((((nn decrease) OR (fold decrease))) OR (a decrease)) ))', query time: 1.59s Refine Results
  1. 1041
  2. 1042

    Trends in Statin Use in Seniors 1999 to 2013: Time Series Analysis by Laura V. Minard (349145)

    Published 2016
    “…The overall proportion of NSSPP beneficiaries dispensed a statin increased approximately 4-fold during the study period. …”
  3. 1043
  4. 1044
  5. 1045
  6. 1046
  7. 1047
  8. 1048
  9. 1049
  10. 1050
  11. 1051
  12. 1052
  13. 1053
  14. 1054

    Table_1_Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease.XLSX by Emilie Faivre (5507582)

    Published 2018
    “…In the present study, we have evaluated the effect of a 6-month treatment of APPsw/PS1dE9 mice with the potent and selective A<sub>2A</sub>R antagonist MSX-3 from 3 to 9-10 months of age. …”
  15. 1055

    Table_3_Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease.XLSX by Emilie Faivre (5507582)

    Published 2018
    “…In the present study, we have evaluated the effect of a 6-month treatment of APPsw/PS1dE9 mice with the potent and selective A<sub>2A</sub>R antagonist MSX-3 from 3 to 9-10 months of age. …”
  16. 1056

    Table_4_Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease.XLSX by Emilie Faivre (5507582)

    Published 2018
    “…In the present study, we have evaluated the effect of a 6-month treatment of APPsw/PS1dE9 mice with the potent and selective A<sub>2A</sub>R antagonist MSX-3 from 3 to 9-10 months of age. …”
  17. 1057

    Image_1_Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease.PDF by Emilie Faivre (5507582)

    Published 2018
    “…In the present study, we have evaluated the effect of a 6-month treatment of APPsw/PS1dE9 mice with the potent and selective A<sub>2A</sub>R antagonist MSX-3 from 3 to 9-10 months of age. …”
  18. 1058
  19. 1059
  20. 1060